Online inquiry

IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6198MR)

This product GTTS-WQ6198MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors, Adenocarcinoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6198MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9147MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ5254MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ11821MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ4538MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ1852MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ8177MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ4381MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ5242MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW